Search

Your search keyword '"Simona Calabrese"' showing total 8 results
Start Over Author "Simona Calabrese" Search Limiters Full Text
8 results on '"Simona Calabrese"'

1. Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia

Author

Daniela Tozzuoli, Alberto Fabbri, Giuseppe Marotta, Francesco Forconi, Francesco Lauria, Simona Calabrese, Rosaria Crupi, Alessandro Gozzetti, and Mariapia Lenoci

Subjects
Oncology, medicine.medical_specialty, Pathology, Chromosomes, Human, Pair 22, medicine.medical_treatment, Chronic lymphocytic leukemia, Trisomy, Chromosomal translocation, Aggressive disease, Disease-Free Survival, Translocation, Genetic, hemic and lymphatic diseases, Internal medicine, medicine, Humans, B-cell chronic lymphocytic leukemia, Chromosomes, Human, Pair 14, Chemotherapy, Chromosomes, Human, Pair 12, business.industry, Cytogenetics, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Cytogenetic Analysis, Female, Good prognosis, business
Abstract

Recurrent cytogenetic abnormalities are typically found in about one third of B-cell chronic lymphocytic leukemia patients (B-CLL) by standard cytogenetic analysis and their prognostic relevance is well known. We report a case of a B-CLL patient showing both trisomy 12 and a t(14;22)(q32;q11). Trisomy 12 is often associated with aggressive disease and resistance to chemotherapy, however, our patient is in good health and currently untreated after 7 years, suggesting in this case a relatively good prognosis and a questionable role for translocations involving the 14q32 locus.

Published
2004
Full Text
View/download PDF

2. Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogentics

Author

Marzia Defina, Rosaria Crupi, Francesco Lauria, M.T. Pirrotta, Alessandro Gozzetti, Simona Calabrese, R. Algeri, Monica Bocchia, and Donatella Raspadori

Subjects
Molecular cytogenetics, CD20, Cancer Research, biology, Concomitant, Chronic lymphocytic leukemia, Genetics, biology.protein, medicine, Cancer research, Myeloid leukemia, medicine.disease, Molecular Biology
Published
2008

3. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

Author

Simona Calabrese, M.T. Pirrotta, Daniela Tozzuoli, Monica Bocchia, Elisabetta Abruzzese, Micaela Ippoliti, Mm Trawinska, Marilina Amabile, Giovanni Martinelli, Marzia Defina, Francesco Lauria, Alessandro Gozzetti, Rosaria Crupi, Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT, Crupi R, Tozzuoli D, Trawinska MM, Defina M, Martinelli G, and Lauria F.

Subjects
Adult, Male, Cancer Research, CD34, Cell Count, IMATINIB, Piperazines, Bone Marrow, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, Aged, CHRONIC MYELOID LEUKEMIA, business.industry, Remission Induction, Myeloid leukemia, Imatinib, Hematology, Middle Aged, Imatinib mesylate, Pyrimidines, Oncology, Immunology, Benzamides, Cancer research, Imatinib Mesylate, Female, business, medicine.drug
Abstract

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

Published
2007

4. Trisomy 8 in chronic lymphocytic leukaemia: a report of two cases

Author

Donatella Raspadori, Daniela Tozzuoli, Alessandro Gozzetti, Mariapia Lenoci, Francesco Zaja, Maristella Tassi, Simona Calabrese, Rosaria Crupi, Francesco Lauria, Gozzetti, A, Calabrese, S, Crupi, R, Zaja, Francesco, Tozzuoli, D, Tassi, M, Raspadori, D, Lenoci, M, and Lauria, F.

Subjects
Male, Cancer Research, Pathology, medicine.medical_specialty, Leukemia, Chronic lymphocytic leukemia, B-Cell, Trisomy, Biology, medicine.disease, Trisomy 8, Chromosomes, Lymphocytic, Genetics, medicine, Pair 8, Humans, Female, Chronic, Molecular Biology, Aged, Chromosomes, Human, Pair 8, Leukemia, Lymphocytic, Chronic, B-Cell, Human
Published
2007

5. Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment

Author

Monica Bocchia, Francesco Lauria, Donatella Raspadori, Maria Teresa Pirrotta, Simona Calabrese, Alessandro Gozzetti, and Rosaria Crupi

Subjects
ABL, Blast Crisis, business.industry, Hematology, General Medicine, medicine.disease, Imatinib treatment, Myelogenous, Leukemia, Immunophenotyping, Imatinib mesylate, medicine, Cancer research, business, Chronic myelogenous leukemia
Published
2007

6. Contents Vol. 117, 2007

Author

Chang-Ki Min, Fabiana Gentilini, Miranda Athanasiou-Metaxa, Kazuaki Yakushiji, Vassilios Kouloulias, Masamitsu Karasawa, Annamaria Frustaci, Seok Lee, Gyeongsin Park, Masataka Sakuraya, Iván Alvarez, Michitoshi Hashiguchi, Kohji Yoshimoto, Ki-Ryang Koh, Hiroshi Handa, Simona Calabrese, Dong-Gun Lee, Hiroyuki Irisawa, Hendrik Veelken, Sung-Jin Moon, Kiyoyuki Hagihara, Woo-Sung Min, Rie Imamura, Takahisa Yamane, Ida Carmosino, Alessandro Gozzetti, Takashi Okamura, Chaido Tsantali, Elvira Grandone, Roberto Latagliata, Jürgen Finke, Mika Nakamae, Giovanni Targher, Koichi Osaki, Maria Rosaria De Cuia, Maria Teresa Pirrotta, Monica Bocchia, Lorella Melillo, Norifumi Tsukamoto, Hideo Koh, Massimo Franchini, Maria Keramida, Yuka Takata, Chun-Choo Kim, Anna-Katharina Thomas-Kaskel, Shuichiro Nagata, Hirohisa Nakamae, Dieter Herchenbach, Maria Rosa Valvano, Anna Levi, Takafumi Matsushima, Younggu Kim, Tatiana Gil Alves Portugal, Korenori Otsubo, Takahiko Nakane, Elena Carretera, Michio Sata, Kensuke Ohta, Erina Sakamoto, Jong Wook Lee, Rosaria Crupi, Jong Weon Choi, Takayuki Saitoh, Francisco Sicilia, Hirokazu Murakami, Donatella Raspadori, Hideaki Ogata, Giuseppe Lippi, Akihiko Yokohama, Giuliana Alimena, Donatella Colaizzo, Francesco Lauria, Fiammetta Natalino, Marina Economou, Myungshin Kim, Leonora Houet, Jose M. Calvo-Villas, Filomena Cappucci, Massimo Breccia, Gianna Maria D'Elia, Yasunobu Takeoka, Juan Espinosa, Eijiro Oku, Masayuki Hino, Yoshihisa Nojima, Arito Yamane, Ritsuko Seki, Nicola Cascavilla, and Nikolaos Gompakis

Subjects
Hematology, General Medicine
Published
2007
Full Text
View/download PDF

7. Subject Index Vol. 117, 2007

Author

Giovanni Targher, Maria Teresa Pirrotta, Filomena Cappucci, Maria Rosaria De Cuia, Hirokazu Murakami, Nikolaos Gompakis, Vassilios Kouloulias, Hideo Koh, Takahisa Yamane, Elvira Grandone, Francisco Sicilia, Masamitsu Karasawa, Chang-Ki Min, Fabiana Gentilini, Nicola Cascavilla, Takafumi Matsushima, Younggu Kim, Takashi Okamura, Tatiana Gil Alves Portugal, Jong Weon Choi, Giuliana Alimena, Gyeongsin Park, Anna Levi, Shuichiro Nagata, Seok Lee, Kensuke Ohta, Fiammetta Natalino, Leonora Houet, Chaido Tsantali, Marina Economou, Donatella Raspadori, Maria Keramida, Rosaria Crupi, Hiroshi Handa, Kiyoyuki Hagihara, Yoshihisa Nojima, Hiroyuki Irisawa, Ivan Alvarez, Norifumi Tsukamoto, Takayuki Saitoh, Hideaki Ogata, Donatella Colaizzo, Giuseppe Lippi, Juan Espinosa, Sung-Jin Moon, Hendrik Veelken, Eijiro Oku, Myungshin Kim, Monica Bocchia, Yuka Takata, Hirohisa Nakamae, Alessandro Gozzetti, Masayuki Hino, Koichi Osaki, Jürgen Finke, Michio Sata, Akihiko Yokohama, Ritsuko Seki, Takahiko Nakane, Erina Sakamoto, Massimo Breccia, Elena Carretera, Annamaria Frustaci, Yasunobu Takeoka, Massimo Franchini, Kazuaki Yakushiji, Anna-Katharina Thomas-Kaskel, Maria Rosa Valvano, Jong Wook Lee, Gianna Maria D'Elia, Lorella Melillo, Simona Calabrese, Dong-Gun Lee, Korenori Otsubo, Masataka Sakuraya, Ki-Ryang Koh, Chun-Choo Kim, Dieter Herchenbach, Roberto Latagliata, Rie Imamura, Jose Manuel Calvo-Villas, Miranda Athanasiou-Metaxa, Francesco Lauria, Kohji Yoshimoto, Arito Yamane, Michitoshi Hashiguchi, Ida Carmosino, Woo-Sung Min, and Mika Nakamae

Subjects
Index (economics), Statistics, Subject (documents), Hematology, General Medicine, Mathematics
Published
2007
Full Text
View/download PDF

8. Evaluation of Ph+/CD34+ Residual Cells in Chronic Myeloid Leukemia Patients after Long Lasting Treatment with Imatinib Mesylate

Author

Rosaria Crupi, Maria Teresa Pirrotta, Alessandro Gozzetti, Micaela Ippoliti, Monica Bocchia, Elisabetta Abruzzese, Francesco Lauria, Daniela Tozzuoli, and Simona Calabrese

Subjects
ABL, business.industry, Immunology, breakpoint cluster region, CD34, Myeloid leukemia, Imatinib, Cell Biology, Hematology, Biochemistry, Imatinib mesylate, medicine.anatomical_structure, hemic and lymphatic diseases, Cancer research, medicine, Bone marrow, Progenitor cell, business, medicine.drug
Abstract

Although the success of imatinib mesylate therapy represents an exciting advance in targeted cancer therapy, it has still to be determined whether responses to this p210 inhibitor in chronic myeloid leukemia (CML) patients will be durable. In fact most of clinical studies agree on the evidence of a persistent molecular disease in the majority of treated patients and altough the absolute level of bcr-abl transcript may vary over the treatment, yet a molecular complete response is of rare observation. In addition, discontinuation of imatinib exerts always in rapid loss of response. In accordance to this the persistence of malignant progenitors in patients in complete cytogenetic response (CCR) after short term imatinib treatment, has been recently demonstrated. In particular, Bathia et al. showed in 12/15 patients studied after a median time of 10 months of imatinib treatment a median of 11% of residual CML CD34+ progenitors in the bone marrow (by FISH Dual Fusion bcr/abl analysis)while only 3/15 patients had no detectable residual CD34+ cells. Less is known about residual Ph+/CD34+ cells surviving after a prolonged therapy with this targeting drug. Thus, we evaluated the amount of bone marrow residual CD34+ cells in 17 CML patients in stable CCR after a long lasting treatment with imatinib. At the time of evaluation, the patients were on conventional dose (400mg) Imatinib for a median time of 48 months (range 36–58 months) having achieved a CCR status (conventionally defined as the complete absence of t(9;22) on caryotypic analysis) within 3 to 6 months of treatment. However all of them still showed molecular disease as detected by nested RT-PCR. Bone marrow CD34+ cell-enriched populations were selected from mononuclear cells using immunomagnetic column separation and were evaluated after cytospin by FISH using a bcr-abl Dual Color Extra Signal Probe(LSI bcr-abl ES, Vysis), that is able to detect bcr-abl fusion in interphase nuclei with a false positive signal rate close to 0. A minimum of 100 CD34+ nuclei per each sample were evaluated. Interestingly, in 8/17 patients no Ph+/CD34+ cells were detected, while in the remaining 9/17 patients a median of 2% (range 0.5–11%) of bcr-abl positive progenitors were still observed. In this small selected serie of patients prolonged treatment with imatinib appears to be correlated with a lower, yet detectable, amount of residual bone marrow Ph+/CD34+ cells when compared to previously published data. This result could be partly explained with the different specificity and sensitivity of the probe used (bcr/abl ES

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results